Pilot Study to Investigate Tirzepatide's Effects on Muscle and Vascular Health in Obese Older Adults

Obesity and type 2 diabetes mellitus (T2DM) are prevalent and debilitating conditions, particularly in the aging population. While Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, effectively reduces weight and improves glycemic control, its specific effects on functional outcomes in older adults remain underexplored. Concerns exist that weight loss from GLP-1/GIP agonists might involve substantial lean muscle mass loss, potentially exacerbating frailty and weakness in this vulnerable demographic. This study addresses the critical gap in understanding Tirzepatide's impact on muscle and vascular health in older adults.

This proposed pilot study, registered as NCT07373834, aims to recruit older adults with obesity. Participants will be randomized to receive either Tirzepatide or a placebo once weekly for 6 months. The primary objective is to evaluate how this treatment affects muscle mass and function, and to determine if changes in muscle mass correlate with changes in functional status over the study period. Secondary endpoints will likely include assessments of vascular health markers, although specific assays were not detailed in the abstract. This design will provide initial data on Tirzepatide's comprehensive physiological impact beyond weight loss in this population.